

RASolve 301

Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC

This is the trial summary as assessed on clinicaltrials.gov

[Study Details](#) | [NCT06881784](#) | [Study of Daraxonrasib \(RMC-6236\) in Previously Treated Patients With RAS Mutated NSCLC \(RASolve 301\)](#) | [ClinicalTrials.gov](#)

Inclusion Criteria:

- At least 18 years old and has provided informed consent.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Histologically confirmed NSCLC, either locally advanced or metastatic, not amenable to curative surgery or radiotherapy.
- Measurable disease per RECIST v1.1.
- Adequate organ function (bone marrow, liver, kidney, coagulation).
- One to two prior lines of therapy including an anti-PD-1/anti-PD(L)-1 agent and platinum-based chemotherapy.
- Documented RAS mutation status, defined as Nonsynonymous mutations in KRAS, NRAS, or HRAS at codons G12X-C (no G12C, G13, and Q61 mutations).
- Able to take oral medications.

Exclusion Criteria:

- Prior therapy with direct RAS-targeted therapy or docetaxel.
- Untreated central nervous system (CNS) metastases.
- Medically significant comorbidities (significant cardiovascular disease, lung disease, or impaired GI function).
- Ongoing anticancer therapy.
- Pregnancy and/or breastfeeding.